Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme

BACKGROUND: Because of the poor outcomes for patients with recurrent glioblastoma multiforme (GBM), and some laboratory and clinical evidence of efficacy using interferon in GBM, we assessed the toxicity and efficacy of temozolomide (TMZ) combined with either short-acting (IFN) or long-acting (pegyl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Groves, M D, Puduvalli, V K, Gilbert, M R, Levin, V A, Conrad, C A, Liu, V H, Hunter, K, Meyers, C, Hess, K R, Alfred Yung, W K
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2009
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2736828/
https://ncbi.nlm.nih.gov/pubmed/19672263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605189
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados